CClinicalTrials.gg
CompletedNCT03362580Updated Jul 9, 2020

Prevalence and Risk Factors of Epiretinal Membrane in Diabetic and Non-diabetic Patients

An observational study in Epiretinal Membrane, sponsored by Laurence Postelmans. Completed at 1 site in Belgium. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by Laurence Postelmans · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
15 Years and older
Sex
All
01

Study summary

Numerous terms have been used to describe epiretinal membrane (ERM): macular pucker, epimacular membrane, surface-wrinkling retinopathy, cellophane maculopathy and preretinal macular fibrosis. It is, by definition, a fibrocellular tissue found on the inner surface of the retina. It is semi-translucent and proliferates on or above the surface of the internal limiting membrane. It causes blurring and metamorphopsia, while mild cases are often asymptomatic.

ERM presence can degrade the acuity and the quality of vision, thus affecting the quality of life. There is evidence that it also has an adverse impact to the treatment options for patients suffering from macular disorders. More specifically, regarding to diabetic retinopathy, ERM seems to have a bidirectional etiopathogenetic relationship with its course and complications.

The aim of this study is to know the prevalence of ERM in the Brussel's population, the risk factors predisposing to ERM formation and if diabetic patients have a significantly higher prevalence of ERM in comparison to general population.

02

Conditions studied

  • Epiretinal Membrane

Browse trials for

Keywords

  • Epiretinal Membrane
  • Diabetes
03

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects examined in the general or diabetes screening consultations of the Ophtalmology Department of the CHU Brugmann Hospital

Inclusion criteria

-Subjects examined in the general or diabetes screening consultations of the Ophthalmology Department of the CHU Brugmann Hospital

Exclusion criteria

Exclusion Criteria:

  • Women pregnant or breast-feeding
  • Hypersensitivity to tropicamide
  • Any macular pathology other than diabetic maculopathy
  • Prior retinal photocoagulation
  • Prior intravitreal injection
  • Prior retinal surgery
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • Group A

    Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older

    Device: Slit lamp examination · Device: Undilated 7-field color fundus photography · Device: Color scan · Device: Spectral domain optical coherence tomography

  • Group B

    Patients non-diagnosed with diabetes mellitus, aged 15 years or older

    Device: Slit lamp examination · Device: Undilated 7-field color fundus photography · Device: Color scan · Device: Spectral domain optical coherence tomography

Interventions

  • DeviceSlit lamp examination

    The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.

  • DeviceUndilated 7-field color fundus photography

    Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.

  • DeviceColor scan

    Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.

  • DeviceSpectral domain optical coherence tomography

    Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.

05

What researchers measure

Primary outcomes

  1. Age

    Age

    Time frame: First standard of care consultation, up to 3 months

  2. Gender

    Gender

    Time frame: First standard of care consultation, up to 3 months

  3. Population sub-type

    Population sub-type: Caucasian, African, Asian, Indian, American or Other

    Time frame: First standard of care consultation, up to 3 months

  4. Diabetes type (for group A)

    Diabetes type (for group A)

    Time frame: First standard of care consultation, up to 3 months

  5. Diabetic Retinopathy classification

    Diabetic Retinopathy classification, if diagnosed (according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) classification)

    Time frame: First standard of care consultation, up to 3 months

  6. Duration of medical treatment of diabetes

    Duration of medical treatment of diabetes (measured in months)

    Time frame: First standard of care consultation, up to 3 months

  7. HbA1C (Glycated Haemoglobin) rate

    HbA1C rate (according to recent blood test)

    Time frame: First standard of care consultation, up to 3 months

  8. Smoking status

    Smoking status

    Time frame: First standard of care consultation, up to 3 months

  9. Previous cataract surgery

    Previous cataract surgery

    Time frame: First standard of care consultation, up to 3 months

  10. Diagnose of ERM

    Diagnose of ERM

    Time frame: First standard of care consultation, up to 3 months

  11. Educational level

    Educational level

    Time frame: First standard of care consultation, up to 3 months

06

Study locations

1 site
  • CHU Brugmann
    Brussels, 1020, Belgium
07

Registry details

Key details

Study ID
NCT03362580
Lead sponsor
Laurence Postelmans
Responsible party
Laurence Postelmans (Head of clinic, Brugmann University Hospital) — Sponsor-investigator
First posted
Dec 5, 2017
Start date
Dec 12, 2017
Primary completion
Oct 10, 2019
Completion
Oct 10, 2019
Last update
Jul 9, 2020

Study contacts

Laurence Postelmans, MD
principal investigator · CHU Brugmann

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion